An intranasal self-amplifying RNA SARS-CoV-2 vaccine produces durable respiratory and systemic immunity
Jennewein, M. F.; Beaver, S.; Battisti, P.; Bakken, J.; Hanson, D.; Mohamath, R.; Singh, J.; Cross, N.; Reed, S.; Gerhardt, A.; Casper, C.; Voigt, E. A.
Show abstract
While mRNA vaccines have been effective in combating SARS-CoV-2, waning of vaccine-induced antibody responses and lack of vaccine-induced respiratory tract immunity contribute to ongoing infection and transmission. In this work, we compare and contrast intranasal (i.n.) and intramuscular (i.m.) administration of a SARS-CoV-2 self-amplifying RNA (saRNA) vaccine delivered by a nanostructured lipid carrier (NLC). Both i.m. and i.n. vaccines induce potent systemic serum neutralizing antibodies, bone marrow-resident IgG-secreting cells, and splenic T cell responses. The i.n. vaccine additionally induces robust respiratory mucosal immune responses, including SARS-CoV-2-reactive lung-resident memory and lung-homing T cell populations. As a booster following previous i.m. vaccination, the i.n. vaccine also elicits the development of mucosal virus-specific T cells. Both the i.m. and i.n. administered vaccines durably protect hamsters from infection-associated morbidity upon viral challenge, significantly reducing viral loads and preventing challenged hamsters from transmitting virus to naive cagemates. This saRNA-NLC vaccines potent systemic immunogenicity, and additional mucosal immunogenicity when delivered i.n., may be key for combating SARS-CoV-2 and other respiratory pathogens.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Durability of DNA-LNP and mRNA-LNP Vaccine-Induced Immunity Against SARS-CoV-2 XBB.1.5 98%
- Heterologous immunization modulates B-cell epitope competition between helper peptides and the MPER segment in MPER/liposome vaccines 97%
- Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates 97%
Similar papers in this journal
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization 98%
- Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine 98%
- Heterologous vaccination regimens with self-amplifying RNA and Adenoviral COVID vaccines induce robust immune responses in mice 97%
Similar papers in this journal
- Preexisting memory CD4 T cells in nÏave individuals confer robust immunity upon hepatitis B vaccination 96%
- Early and Delayed STAT1-Dependent Responses Drive Local Trained Immunity of Macrophages in the Spleen 95%
- Vaccination with mycobacterial lipid loaded nanoparticle leads to lipid antigen persistence and memory differentiation of antigen-specific T cells 95%
Similar papers in this journal
- Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity 97%
- MDSC depletion during immunization with heat-killed Mycobacterium tuberculosis increases protection against BCG infection. 96%
- Polymeric Pathogen-like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus 96%
Similar papers in this journal
- Class switch towards non-inflammatory IgG isotypes after repeated SARS-CoV-2 mRNA vaccination 97%
- Longitudinal Analysis Reveals Distinct Antibody and Memory B Cell Responses in SARS-CoV2 Naïve and Recovered Individuals Following mRNA Vaccination 96%
- The BNT162b2 mRNA vaccine induces polyfunctional T cell responses with features of longevity. 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.